Genome-first analyses in UK Biobank and All of Us support RBM20 as an arrhythmogenic DCM gene, with an etiologic fraction of ...

Shawn Davis, MD, discusses what access and policy changes are needed to close the coverage gap. Glucagon-like peptide-1 ...

Amy Leader, DrPH, MPH, explains that trust is key to clinical trial enrollment at an Institute for Value-Based Medicine event in Philadelphia. Leader said many large cancer centers are working more ...

Amy Leader, DrPH, MPH, explains that trust is key to clinical trial enrollment at an Institute for Value-Based Medicine event in Philadelphia. 259 Prospect Plains Rd, Bldg H Cranbury, NJ 08512 ...

An Excel-based actuarial model (1 million lives; 49% eligible; 10% treated) estimated semaglutide coverage could be ...

Environmental triggers were reported by 69.4% of patients, most commonly water/handwashing, chemical irritants, contact ...

Sparsentan received full FDA approval for FSGS in patients aged 8–75 years, addressing a rare, progressive glomerulopathy ...

The mCRPC section's reorganization by prior treatment exposure reflects how ARPI and docetaxel use in the hormone-sensitive ...

As HIV care continues to evolve, 2-drug regimens are emerging as a key strategy to balance efficacy with long-term ...

Benjamin Lockshin, MD, FAAD, examines the non-clinical reasons driving real-world treatment discontinuation and explains how ...

Real-world persistence data for tildrakizumab paint an encouraging picture of long-term treatment durability, with ...

Bone-only, osteoblastic disease and the absence of prior ARPI exposure define the optimal radium-223 candidate, while ...